GNTA News Genta Appoints Dr. Brian Leyland-Jones
Post# of 144503
GNTA News Genta Appoints Dr. Brian Leyland-Jones and Richard J. Moran to Its Board of Directors
2012-04-24 08:05 ET - News Release
BERKELEY HEIGHTS, N.J., April 24, 2012 (GLOBE NEWSWIRE) -- Genta Incorporated (OTCBB:GNTA) announced today the appointments of Dr. Brian Leyland-Jones and Richard J. Moran, as members of the Company's Board of Directors. The Company also announced the retirement from the Board of Dr. Daniel D. Von Hoff.
Dr. Raymond P. Warrell, Jr., Genta's Board Chairman and Chief Executive Officer commented: "The Genta team is delighted to welcome our new independent directors. Prior to his retirement as Senior Vice-President at Genta, Dick Moran had worked closely with the Board during his tenure, following a career in finance at Johnson & Johnson that spanned more than 20 years. Dr. Leyland-Jones is a leader in pharmacology, oncology drug development, and genomic approaches in breast cancer. Both new members will extend the Board's leadership in key areas of Genta's business."
"The Board extends our deepest gratitude to Dan Von Hoff, who has served on the Genta Board for 12 years. With this extraordinary service, Dan has provided guidance, leadership, and advice to both management and to his colleagues on the Board. In no small measure, the turnaround in progress at Genta reflects contributions from the experience for which he is internationally renowned. We wish him c
(0)
(0)